Drugs / nacubactam
nacubactam
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03174795 | Jul → Dec 2017 | urinary tract infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03182504 | Jun → Aug 2017 | gram-negative bacterial infections | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02975388 | Dec 2016 → Jul 2017 | impaired renal function disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02972255 | Oct 2016 → Mar 2017 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02134834 | May → Aug 2014 | bacterial infectious disease | Meiji Seika Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05905055 | Sep 2023 → Sep 2025 | acute pyelonephritis, bacterial pneumonia | Meiji Seika Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05887908 | May 2023 → Nov 2024 | acute pyelonephritis | Meiji Seika Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nacubactam | “A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam.” PMID 42059789 ↗ Apr 2026 |
| Known as | FPI-1459 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989959 ↗ |
| Known as | OP0595 | “Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam.” PMID 42134354 ↗ May 20261“A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595” NCT02134834 ↗ |
| Known as | RG-6080 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989959 ↗ |
| Known as | RO7079901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03174795 ↗ |
| Action | Inhibit | “novel bicyclic non-β-lactam β-lactamase inhibitor” PMID 42059789 ↗ Apr 2026 |
| Modality | Small molecule | “Nacubactam is a novel bicyclic non-β-lactam β-lactamase inhibitor” PMID 42059789 ↗ Apr 2026 |
| Route | Intravenous | “OP0595 Administered Intravenously” NCT02134834 ↗ |